Evelo Biosciences, Inc. (EVLO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 64.44 Million USD | -26.66% |
| 2021 | 87.87 Million USD | -3.05% |
| 2020 | 90.63 Million USD | -0.31% |
| 2019 | 90.92 Million USD | -43.13% |
| 2018 | 159.86 Million USD | 265.09% |
| 2017 | 43.78 Million USD | 135.8% |
| 2016 | 18.57 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 20.81 Million USD | -50.4% |
| 2023 Q1 | 41.97 Million USD | -34.87% |
| 2023 Q3 | 20.62 Million USD | -0.92% |
| 2022 Q3 | 86.33 Million USD | -22.85% |
| 2022 Q2 | 111.9 Million USD | 90.23% |
| 2022 Q1 | 58.82 Million USD | -33.06% |
| 2022 FY | 64.44 Million USD | -26.66% |
| 2022 Q4 | 64.44 Million USD | -25.36% |
| 2021 Q4 | 87.87 Million USD | -24.55% |
| 2021 Q1 | 153.04 Million USD | 68.85% |
| 2021 Q2 | 145.05 Million USD | -5.22% |
| 2021 FY | 87.87 Million USD | -3.05% |
| 2021 Q3 | 116.45 Million USD | -19.72% |
| 2020 Q4 | 90.63 Million USD | -13.54% |
| 2020 Q2 | 113.9 Million USD | 36.99% |
| 2020 FY | 90.63 Million USD | -0.31% |
| 2020 Q1 | 83.14 Million USD | -8.55% |
| 2020 Q3 | 104.83 Million USD | -7.96% |
| 2019 Q2 | 126.2 Million USD | -11.08% |
| 2019 FY | 90.92 Million USD | -43.13% |
| 2019 Q4 | 90.92 Million USD | -18.19% |
| 2019 Q3 | 111.14 Million USD | -11.94% |
| 2019 Q1 | 141.93 Million USD | -11.22% |
| 2018 Q3 | 175.6 Million USD | -6.74% |
| 2018 FY | 159.86 Million USD | 265.09% |
| 2018 Q4 | 159.86 Million USD | -8.96% |
| 2018 Q2 | 188.28 Million USD | 53.94% |
| 2018 Q1 | 122.31 Million USD | 179.33% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 43.78 Million USD | 0.0% |
| 2017 FY | 43.78 Million USD | 135.8% |
| 2016 FY | 18.57 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -21442.879% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -1023.448% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -338.523% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -106.442% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -1901.273% |
| Better Therapeutics, Inc. | 22.94 Million USD | -180.874% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -124.721% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -1628.979% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -213.673% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -205.075% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -2637.848% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 9.234% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -146.513% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -84698.6% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -429.55% |
| Molecular Templates, Inc. | 35.38 Million USD | -82.124% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -1374.081% |
| NexImmune, Inc. | 8.59 Million USD | -649.842% |
| Orgenesis Inc. | 14.55 Million USD | -342.833% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -446.018% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -51600.457% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -1034.444% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -16327.925% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 86.371% |
| Statera Biopharma, Inc. | 21.16 Million USD | -204.402% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -537.714% |
| Trevena, Inc. | 40.6 Million USD | -58.702% |
| Vaxxinity, Inc. | 44.35 Million USD | -45.291% |
| Vaccinex, Inc. | 3.63 Million USD | -1674.745% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -162400.0% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -13.669% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -11496.052% |